16 terminated. 16 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Terminated 16 |
| Phase 2 | 3 | Terminated 3 |
Follow Recurrent Adult Diffuse Large Cell Lymphoma: new trials by email Literature Review of Recurrent Adult Diffuse Large Cell Lymphoma trials Research Report on Recurrent Adult Diffuse Large Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 72 | 2014-09-01 | 2015-08-20 |
| Ipilimumab and Local Radiation for Selected Solid Tumors Ipilimumab, Radiation therapy - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | Stanford University | 3 | 2013-02-01 | 2024-01-24 |
| Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma lenalidomide, vorinostat, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | City of Hope Medical Center | 30 | 2010-05-01 | 2010-12-09 |
| Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma lenalidomide, rituximab, polymerase chain reaction - Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis | Phase 1 | Terminated | Case Comprehensive Cancer Center | 5 | 2010-01-01 | 2015-11-26 |
| Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma obatoclax mesylate, bortezomib, laboratory biomarker analysis - Adult Non-Hodgkin Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 18 | 2007-12-01 | 2015-12-04 |
| PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma tanespimycin, belinostat, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2006-05-01 | 2013-05-16 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma alvocidib - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 46 | 2005-12-01 | 2016-08-08 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma fenretinide, rituximab - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2005-10-01 | 2014-10-06 |
| 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer tanespimycin, bortezomib - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 74 | 2005-04-01 | 2013-06-04 |
| Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas tanespimycin, bortezomib, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2004-11-01 | 2014-02-24 |
| SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma ispinesib, laboratory biomarker analysis, pharmacological study - Adult Grade III Lymphomatoid Granulomatosis, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 | Terminated | National Cancer Institute (NCI) | 31 | 2004-11-01 | 2013-01-14 |
| MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma ipilimumab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 18 | 2004-06-01 | 2014-05-30 |
| Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma oblimersen sodium, gemcitabine hydrochloride, pharmacological study - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 15 | 2003-03-01 | 2013-01-25 |
| Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies indium In 111 anti-CD45 monoclonal antibody BC8, yttrium Y 90 anti-CD45 monoclonal antibody BC8, peripheral blood stem cell transplantation - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 2 | 1999-09-01 | 2021-04-02 |
| Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma tanespimycin - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 45 | 1999-06-01 | 2013-12-16 |
Leukemia, Lymphocytic, Chronic, B-Cell (16) · Lymphoma, B-Cell, Marginal Zone (16) · Lymphoma, Follicular (16) · Lymphoma, Large B-Cell, Diffuse (16) · Lymphoma, Mantle-Cell (16) · Lymphoma, Non-Hodgkin (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Burkitt Lymphoma (13) · Waldenstrom Macroglobulinemia (13) · Lymphoma, Large-Cell, Immunoblastic (12) · Hodgkin Disease (9) · Lymphoma, T-Cell, Cutaneous (8) · Mycosis Fungoides (8) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (8) · Sezary Syndrome (8)
Chronic Disease (16) · Disease Attributes (16) · Hematologic Diseases (16) · Hemic and Lymphatic Diseases (16) · Immune System Diseases (16) · Immunoproliferative Disorders (16) · Leukemia (16) · Leukemia, B-Cell (16) · Leukemia, Lymphoid (16) · Lymphatic Diseases (16) · Lymphoma (16) · Lymphoma, B-Cell (16) · Lymphoproliferative Disorders (16) · Neoplasms (16) · Neoplasms by Histologic Type (16)
tanespimycin (4) · Bortezomib (3) · Rituximab (3) · CTLA-4 Antigen (2) · Ipilimumab (2) · Lenalidomide (2) · Amplified Fragment Length Polymorphism Analysis (1) · Base Sequence (1) · Bendamustine Hydrochloride (1) · CK0238273 (1) · Fenretinide (1) · Flow Cytometry (1) · Gemcitabine (1) · Indium (1) · Peripheral Blood Stem Cell Transplantation (1)
National Cancer Institute (NCI) (11) · Case Comprehensive Cancer Center (1) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Stanford University (1) · Wake Forest University Health Sciences (1)
United States (16)
Ajay Gopal (2) · Charles Erlichman (1) · George A. Fisher, MD, PhD (1) · George Wilding (1) · Jean Grem (1) · Jeffrey Jones (1) · Joseph Tuscano (1) · Kristie Blum (1) · Leslie Popplewell (1) · Patricia LoRusso (1) · Robert Dean, MD (1) · Stephen Ansell (1) · Yvette Kasamon (1) · Zanetta Lamar (1)
P30CA015083 (2), U01CA069912 (2), U01CA076576 (2), N01CM00070 (1), P01CA044991 (1), P30CA012197 (1), P30CA015704 (1), P30CA016058 (1), R21CA119519 (1), U01CA062487 (1), U01CA062491 (1), U01CA062505 (1), U01CA121947 (1)